Name (Synonyms) | Correlation | |
---|---|---|
drug1841 | Placebo for Hydroxychloroquine Wiki | 1.00 |
drug1840 | Placebo for Azithromycin Wiki | 1.00 |
drug263 | Azithromycin (Azithro) Wiki | 1.00 |
drug1087 | Hydroxychloroquine (HCQ) Wiki | 0.50 |
drug1822 | Placebo Wiki | 0.06 |
There is one clinical trial.
The study is a prospective, randomized, placebo-controlled, single-blind phase 2 clinical study of the efficacy and safety of CERC-002, a potent inhibitor of LIGHT, for the treatment of patients with COVID-19 pneumonia who have mild to moderate ARDS. LIGHT is a cytokine in the TNF super family (TNFSF14) which drives inflammation and induces many other cytokines including IL-1, IL-6 and GM-CSF. LIGHT levels have been shown to be elevated in COVID-19 infected patients and inhibiting LIGHT is hypothesized to ameliorate the cytokine storm which has shown to be a major factor in progression of ARDS. The study will assess the efficacy and safety of CERC-002 in patients with severe COVID-19 over a 28 day period as single dose on top of standard of care.
Description: Respiratory failure defined based on resource utilization requiring at least one of the following: Endotracheal intubation and mechanical ventilation Oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen ≥0.5) Noninvasive positive pressure ventilation, Extracorporeal membrane oxygenation
Measure: Proportion of patient alive and free of respiratory failure Time: Baseline to Day 28Description: 1-month mortality
Measure: Proportion of subjects who are alive Time: Baseline to Day 28